Discounts Help Prompt UK’s NICE Turnaround on Dupixent and Ocrevus

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

After initially saying no, the UK health technology appraisal body, NICE, has recommended for use on the National Health Service Sanofi/Regeneron’s Dupixent and Roche’s Ocrevus. Confidential discounts helped convince NICE.

nerve cells, concept for neurodegenerative and neurological disease
Nerve signals between the brain and other parts of the body are disrupted by damage to the myelin and nerve fibers in patients with multiple sclerosis.

NICE, the health technology appraisal institute for England and Wales, has issued two pieces of final draft guidance reversing earlier recommendations that found Roche’s multiple sclerosis drug Ocrevus (ocrelizumab) and Sanofi/Regeneron Pharmaceuticals Inc.’s Dupixent (dupilumab) for eczema to be too expensive for use on the National Health Service. In both cases discounts helped secure a turnaround.

Final draft guidance published by NICE on June 22 recommends Ocrevus for treating relapsing remitting MS (RRMS) in adults with...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

PS-MarketAccess (Premium-2): Why Financial Scammers Are So Successful Targeting Doctors

 
• By Nabil

Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.

Australia Considers New 'Bridging Fund' Among 50 Recommendations For HTA Reform

 
• By Neena Brizmohun

Industry says it is ready to work with the government on the recommendations from a major review of Australia’s health technology assessment system that covers areas such as discount rate reductions and setting up a separate budgetary allocation to temporarily subsidize access to certain drugs.

Responsible Antimicrobial Manufacturing A Must For UK’s Subscription Model Applicants

 
• By Eliza Slawther

The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.

Use AI In Health Technology Assessments Only When Valuable, England’s NICE Tells Pharma Firms

 
• By Eliza Slawther

Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.

More from Market Access

analysis

Shot Across The Bow? Express Scripts Lawsuit Seeks To Derail Fall-Out From FTC PBM Report

 
• By Cathy Kelly

Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.

‘Alternative' PBMs Say Vertical Integration Unfairly Carving Them Out Of The Game

 
• By Sarah Karlin-Smith

Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.

UK MHRA First-Half New Drug Approvals Show Overwhelming Use Of EU Reliance Procedures

 
• By Ian Schofield

The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.